Bhang and colleagues [36] looked at a population of NSCLC cells sensitive to EGFR inhibitors using this technique and found extremely rare (below 0.05%), but pre-existing clones that could expand in the presence of the drug. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.